Relmada Therapeutics (RLMD) Other Gross PP&E Adjustments (2015 - 2026)
Relmada Therapeutics (RLMD) reported Other Gross PP&E Adjustments of -$312900.0 for Q1 2026, little changed year-over-year from -$312600.6 in Q1 2025, and down 42.23% on a QoQ basis from -$220000.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 11 years of Other Gross PP&E Adjustments data on file, last reported at -$312900.0 in Q1 2026.
- Quarterly Other Gross PP&E Adjustments changed 0.1% year-over-year to -$312900.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 8.32% YoY) and the FY2025 annual result came in at -$220000.0, up 39.33% from the prior year.
- Other Gross PP&E Adjustments retreated to -$312900.0 in Q1 2026 per RLMD's latest filing, from -$220000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$174000.0 in Q4 2023 and bottomed at -$362600.0 in Q4 2024.
- The 4-year median for Other Gross PP&E Adjustments is -$254650.0 (2024), against an average of -$263425.0.
- The widest annual swing landed in 2024, when Other Gross PP&E Adjustments sank 108.39%; it then soared 39.33% in 2025.
- Tracing RLMD's Other Gross PP&E Adjustments over 4 years: stood at -$174000.0 in 2023, then slumped by 108.39% to -$362600.0 in 2024, then soared by 39.33% to -$220000.0 in 2025, then slumped by 42.23% to -$312900.0 in 2026.
- Per Business Quant, the three latest RLMD Other Gross PP&E Adjustments figures stand at -$312900.0 (Q1 2026), -$220000.0 (Q4 2025), and -$215400.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -312,900.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -312,900.00 |
| Mar 31, 2026 | -312,900.00 |
| Dec 31, 2025 | -220,000.00 |
| Dec 31, 2025 | -220,000.00 |
| Sep 30, 2025 | -215,400.00 |
| Sep 30, 2025 | -215,400.00 |
| Jun 30, 2025 | -257,000.00 |
| Jun 30, 2025 | -257,000.00 |
| Mar 31, 2025 | -313,200.00 |
| Mar 31, 2025 | -313,200.00 |
| Dec 31, 2024 | -362,600.00 |
| Dec 31, 2024 | -362,600.00 |
| Sep 30, 2024 | -252,300.00 |
| Sep 30, 2024 | -252,300.00 |
| Dec 31, 2023 | -174,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Dec 31, 2021 | 16,700.00 |
| Dec 31, 2021 | 16,700.00 |
| Sep 30, 2021 | 16,700.00 |
| Sep 30, 2021 | 16,700.00 |
| Jun 30, 2021 | 16,700.00 |
| Jun 30, 2021 | 16,700.00 |
| Mar 31, 2021 | 16,700.00 |
| Mar 31, 2021 | 16,700.00 |
| Dec 31, 2020 | 15,400.00 |
| Dec 31, 2020 | 15,400.00 |
| Sep 30, 2020 | 16,700.00 |
| Sep 30, 2020 | 16,700.00 |
| Jun 30, 2020 | 16,700.00 |
| Jun 30, 2020 | 16,700.00 |
| Mar 31, 2020 | 16,700.00 |
| Mar 31, 2020 | 16,700.00 |
| Dec 31, 2019 | 16,700.00 |
| Dec 31, 2019 | 16,700.00 |
| Sep 30, 2019 | 16,700.00 |
| Sep 30, 2019 | 16,700.00 |
| Jun 30, 2019 | 16,700.00 |
| Jun 30, 2019 | 16,700.00 |
| Mar 31, 2019 | 16,700.00 |
| Mar 31, 2019 | 16,700.00 |
| Dec 31, 2018 | 16,700.00 |
| Dec 31, 2018 | 16,700.00 |
| Sep 30, 2018 | 16,700.00 |
| Sep 30, 2018 | 16,700.00 |
| Jun 30, 2018 | 16,700.00 |
| Jun 30, 2018 | 16,700.00 |
| Mar 31, 2018 | 6,900.00 |
| Mar 31, 2018 | 6,900.00 |
| Dec 31, 2017 | 6,900.00 |
| Dec 31, 2017 | 6,900.00 |
| Sep 30, 2017 | 6,900.00 |
| Sep 30, 2017 | 6,900.00 |
| Jun 30, 2017 | 4,300.00 |
| Jun 30, 2017 | 4,300.00 |
| Mar 31, 2017 | 641,800.00 |
| Mar 31, 2017 | 641,800.00 |
| Dec 31, 2016 | 621,500.00 |
| Dec 31, 2016 | 621,500.00 |
| Sep 30, 2016 | 619,100.00 |
| Sep 30, 2016 | 619,100.00 |
| Jun 30, 2016 | 595,100.00 |
| Jun 30, 2016 | 595,100.00 |
| Mar 31, 2016 | 573,600.00 |
| Mar 31, 2016 | 573,600.00 |
| Dec 31, 2015 | 552,100.00 |
| Dec 31, 2015 | 552,100.00 |
| Jun 30, 2015 | 34,300.00 |
| Jun 30, 2015 | 34,300.00 |